Latest On Sinovac Biotech Ltd (SVA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-08-03 11:16 EST | News | Sinovac's COVID shot approved for use in children aged 6 months to 3 years in Hong Kong | N/A |  |
| 2022-07-19 22:49 EST | News | Sinovac begins late-stage trial of influenza vaccine in Chile | N/A | |
| 2022-07-14 11:22 EST | News | Sinovac COVID-19 vaccine gets emergency use nod in Brazil for children aged 3-5 years | N/A | |
| 2022-06-27 16:22 EST | News | Sinovac Biotech COVID-19 vaccine conditionally registered in South Africa | N/A | |
| 2022-05-17 17:39 EST | News | CEPI to fund Sabin Vaccine Institute trial to see efficacy of lower doses of COVID boosters | N/A | |
| 2022-05-02 09:21 EST | News | Sinovac Biotech GAAP EPS of $74.27, revenue of $19.4B | N/A | |
| 2022-04-18 06:29 EST | News | Sinovac Biotech's Omicron-specific vaccine cleared for clinical trial in Hong Kong | N/A | |
| 2022-04-08 05:27 EST | News | Supply chain on watch as Shanghai lockdown grows in severity | N/A | |
| 2022-03-25 00:55 EST | News | Sinovac booster shows 98% protection against death/severe COVID in people over 60 in study | N/A | |
| 2022-01-25 02:45 EST | News | AstraZeneca, Pfizer/ BioNTech or J&J shots found to boost effect of Sinovac COVID-19 vaccine | N/A | |
| 2021-12-31 11:54 EST | News | Sinovac Biotech reports 1H results | N/A | |
| 2021-12-23 20:56 EST | News | Three doses of Sinovac's COVID-19 vaccine fail to protect against Omicron variant: Study | N/A | |
| 2021-12-12 12:27 EST | News | Greatly Transformed Sinovac Set To Reawaken On Wall Street? | N/A | |
| 2021-10-12 13:29 EST | News | WHO recommends an additional COVID-19 vaccine for immunocompromised people | N/A | |
| 2021-09-09 12:31 EST | News | Sinovac’s COVID-19 vaccine booster shot shows better neutralization breadth to VOCs | N/A | |
| 2021-09-08 16:26 EST | News | Sinovac's COVID-19 vaccine gets emergency use approval in Chile | N/A | |
| 2021-09-07 20:54 EST | News | Sinovac's COVID-19 booster shot reverses drop in antibody activities against Delta: Study | N/A | |
| 2021-09-03 23:12 EST | News | China is struggling to expand COVID-19 vaccination drive - official | N/A | |
| 2021-08-17 21:20 EST | News | Sinovac COVID-19 vaccine is linked to higher risk of Bell's Palsy - study | N/A | |
| 2021-08-10 12:23 EST | News | Sinovac COVID vaccine demonstrates strong immune response with booster shot | N/A | |
| 2021-07-27 16:55 EST | News | Sinovac's COVID-19 vaccine antibodies fade after six months: Study | N/A | |
| 2021-07-22 03:01 EST | News | WHO seeks more data on Sinovac Biotech’s COVID-19 vaccine - WSJ | N/A | |
| 2021-07-22 02:58 EST | News | Pfizer/ BioNTech and AstraZeneca to dominate global COVID-19 vaccine supply in 2021 | N/A | |
| 2021-07-22 02:58 EST | News | Brazilian study indicates Sinovac shot benefit when majority of population vaccinated | N/A | |
| 2021-07-22 02:57 EST | News | Sinovac obtains WHO emergency use listing for COVID-19 shot | N/A | |
| 2021-07-22 02:36 EST | News | Some Chinese vaccines less effective against COVID-19 Delta variant - Reuters | N/A | |
| 2021-07-22 02:33 EST | News | Sinovac’s COVID-19 vaccine shows potential to induce strong immune responses in children aged 3 to 17 | N/A | |
| 2021-07-22 02:26 EST | News | Some countries consider booster shots for those who received Sinovac COVID-19 shot | N/A | |
| 2021-07-22 02:23 EST | News | Sinovac to supply 380M doses of COVID-19 vaccine to COVAX | N/A | |
| 2021-07-22 02:23 EST | News | Chinese COVID-19 shots have nearly 70% efficacy against Delta variant, scientist says | N/A | |
| 2021-07-22 02:20 EST | News | Pfizer/BioNTech, Moderna vaccine effect impacted by COVID-19 Lambda variant | N/A | |
| 2021-07-22 02:15 EST | News | Pfizer/BioNTech COVID-19 shot triggers higher antibody levels compared to Sinovac vaccine: new study | N/A | |
| 2021-05-05 03:41 EST | News | Sinovac’s COVID-19 shot undergoes rolling review in Europe | N/A | |
| 2021-04-16 20:02 EST | News | Sinovac vaccine 67% effective against symptomatic infection in real-world study - Reuters | N/A | |
| 2021-02-18 22:43 EST | News | Sinovac’s COVID-19 vaccine is said to be effective against new variants | N/A | |
| 2021-02-10 19:05 EST | News | Sinovac's COVID-19 vaccine wins conditional marketing authorization in China | N/A | |
| 2021-02-06 08:03 EST | News | Sinovac’s announces late-stage data for COVID-19 vaccine candidate | N/A | |
| 2021-01-18 00:32 EST | News | AstraZeneca and Sinovac COVID-19 shots get emergency nod in Brazil | N/A | |
| 2021-01-16 16:39 EST | Financials | Company financials have been released. | Neutral | |
| 2021-01-15 12:44 EST | Financials | Company financials have been released. | Neutral | |
| 2021-01-15 12:44 EST | Analyst Rating | The Analyst Target Price has increased from $0 to $6. | Neutral | |
| 2021-01-13 19:11 EST | News | Philippines to obtain additional 20M doses of AstraZeneca's COVID-19 jab | N/A | |
| 2021-01-13 19:11 EST | News | Sinovac's COVID-19 shot demonstrates four different protection rates, Brazil results shows 50.4% efficacy | N/A | |
| 2021-01-01 13:15 EST | News | Sinopharm gets conditional approval for COVID-19 vaccine in China | N/A | |
| 2020-12-22 09:11 EST | News | Sinovac’s COVID-19 shot effective in Brazil trials - WSJ | N/A | |
| 2020-12-14 08:12 EST | News | Singapore approves Pfizer-BioNTech's COVID-19 jab | N/A | |
| 2020-12-11 12:18 EST | News | Hong Kong secures deals for 15M COVID-19 shots, with first lot arriving in January | N/A | |
| 2020-12-07 11:04 EST | News | Sinovac secures ~$500M funding for COVID-19 vaccine development | N/A | |
| 2020-12-07 11:04 EST | News | Sinovac Biotech reports Q3 results | N/A | |
| 2020-11-19 00:25 EST | News | Sinovac's COVID-19 vaccine 'successful' in mid-stage trials | N/A | |
About Sinovac Biotech Ltd (SVA):
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella, pneumococcal polysaccharide, and Sabin inactivated polio vaccines. Further, it is developing rubella vaccine; Sabin-strain inactivated polio vaccine; Sars-coVv-2 (COVID-19) vaccine; and quadrivalent influenza vaccine. Sinovac Biotech Ltd. has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; Dynavax Technologies Corporation to develop a vaccine to prevent COVID-19; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. The company was founded in 1999 and is based in Beijing, the People's Republic of China.
General
- Name Sinovac Biotech Ltd
- Symbol SVA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 910
- Fiscal Year EndDecember
- IPO Date2003-11-03
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.sinovacbio.com
View More
Valuation
- Trailing PE 38.51
- Price/Sales (Trailing 12 Mt.) 1.83
- Price/Book (Most Recent Quarter) 1.82
- Enterprise Value Revenue 1.12
- Enterprise Value EBITDA 5.6
View More
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin 9%
- Operating Margin 18%
- Return on Assets 6%
- Return on Equity 13%
- Revenue 264.28 million
- Earnings Per Share $0.17
- Revenue Per Share $2.67
- Gross Profit 213.58 million
- Quarterly Earnings Growth 79.4%
View More
Highlights
- Market Capitalization 460.25 million
- EBITDA 51.39 million
- Analyst Target Price $6
- Book Value Per Share $3.10
View More
Share Statistics
- Shares Outstanding 98.9 million
- Shares Float 43.95 million
- % Held by Insiders 4346%
- % Held by Institutions 33.94%
- Shares Short 200105
- Shares Short Prior Month 200105
View More
Technicals
- Beta 0.05
- 52 Week High $6.47
- 52 Week Low $6.47
- 50 Day Moving Average 6.47
- 200 Day Moving Average 6.47
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Sinovac Biotech Ltd (SVA) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Sinovac Biotech Ltd (SVA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-07 | $115.45 million | $0.08 | ||
| 2020-06-30 | 2020-09-30 | $52.33 million | $0.10 | ||
| 2020-03-31 | 2020-06-30 | $N/A | -$0.05 | ||
| 2019-12-31 | 2020-03-31 | $N/A | -$0.07 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $64.34 million | $0.19 | ||
| 2019-06-30 | 2019-09-30 | $64.05 million | $0.06 | ||
| 2019-03-31 | 2019-06-30 | $36.55 million | $0.11 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $53.58 million | $0.01 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $53.58 million | -$0.02 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $46.45 million | $0.12 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $47.34 million | $0.10 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $107.44 million | $0.14 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $53.72 million | $0.13 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $66.91 million | $0.13 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $33.45 million | $0.10 | ||
| 2016-12-31 | 2017-03-31 | $31.37 million | $0.10 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $28.74 million | $0.08 | ||
| 2016-06-30 | 2016-09-30 | $1.38 million | $0.06 | ||
| 2016-03-31 | 2016-06-30 | $10.95 million | -$0.17 | ||
| 2015-12-31 | 2016-03-31 | $22.95 million | -$0.02 | $0.00 | |
| 2015-09-30 | 2015-12-31 | $16.76 million | $-0.00 | -$0.02 | 99.5% |
| 2015-06-30 | 2015-09-30 | $18.49 million | -$0.03 | -$0.01 | -200% |
| 2015-03-31 | 2015-06-30 | $9.21 million | $0.04 | -$0.02 | 300% |
| 2014-12-31 | 2015-03-31 | $20.32 million | -$0.04 | $0.00 | |
| 2014-09-30 | 2014-11-14 | $17.15 million | $0.00 | -$0.01 | 116% |
| 2014-06-30 | 2014-09-30 | $12.09 million | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $13.55 million | -$0.04 | -$0.03 | -34.67% |
| 2013-12-31 | 2014-03-31 | $22.95 million | $0.00 | -$0.01 | 101% |
| 2013-09-30 | 2013-12-31 | $22.08 million | $0.10 | -$0.02 | 598% |
| 2013-06-30 | 2013-09-30 | $17.45 million | $0.04 | -$0.06 | 166.67% |
| 2013-03-31 | 2013-06-30 | $10.05 million | $0.02 | -$0.10 | 120% |
| 2012-12-31 | 2013-03-31 | $19.59 million | -$0.04 | $0.00 | |
| 2012-09-30 | 2012-12-31 | $14.29 million | -$0.08 | -$0.03 | -179% |
| 2012-06-30 | 2012-09-30 | $9.37 million | -$0.05 | -$0.10 | 45.4% |
| 2012-03-31 | 2012-06-30 | $5.97 million | -$0.02 | -$0.13 | 84.62% |
| 2011-12-31 | 2012-03-31 | $21.14 million | -$0.10 | $0.03 | -442.67% |
| 2011-09-30 | 2011-12-31 | $15.36 million | $0.05 | $0.02 | 148% |
| 2011-06-30 | 2011-09-30 | $15.66 million | -$0.04 | -$0.01 | -300% |
| 2011-03-31 | 2011-06-30 | $4.68 million | $0.02 | $0.01 | 100% |
| 2010-12-31 | 2011-03-31 | $9.14 million | -$0.05 | $0.02 | -356.5% |
| 2010-09-30 | 2010-11-15 | $9.55 million | -$0.01 | $0.02 | -150% |
| 2010-06-30 | 2010-08-16 | $10.26 million | $0.02 | $0.01 | 100% |
| 2010-03-31 | 2010-04-06 | $4.44 million | $0.21 | $0.25 | -16% |
| 2009-09-30 | 2009-11-15 | $21.23 million | $0.12 | $0.08 | 50% |
| 2009-06-30 | 2009-08-19 | $20.02 million | $0.14 | $0.01 | 1300% |
| 2009-03-31 | 2009-05-15 | $6.57 million | $0.00 | ||
| 2008-09-30 | 2008-11-18 | $8.75 million | $0.02 | $0.03 | -33.33% |
| 2008-06-30 | 2008-08-13 | $16.52 million | $0.08 | $0.08 | 0% |
| 2008-03-31 | 2008-05-16 | $8.86 million | $0.04 | ||
| 2007-12-31 | 2008-03-31 | $9.2 million | $0.05 | $0.05 | 0% |
| 2007-09-30 | 2007-12-11 | $10.83 million | $0.05 | ||
| 2007-06-30 | 2007-06-30 | $9.54 million | $0.09 |
Sinovac Biotech Ltd (SVA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | 25.95 million | 14.45 million | N/A | N/A | 5.66 million |
| Income Before Tax | 26.81 million | -101000 | N/A | N/A | 14.56 million |
| Selling General Administrative | 47.23 million | 29.79 million | N/A | N/A | 34.4 million |
| Gross Profit | 101.34 million | 44.77 million | N/A | N/A | 54 million |
| Ebit | 27.68 million | 1.89 million | N/A | N/A | 13.94 million |
| Operating Income | 27.78 million | -178000 | N/A | N/A | 13.94 million |
| Income Tax Expense | 5.66 million | 1.17 million | -1.06 million | -3.29 million | 2.86 million |
| Total Revenue | 115.45 million | 52.33 million | N/A | N/A | 64.34 million |
| Cost of Revenue | 14.11 million | 7.56 million | N/A | N/A | 10.35 million |
| Total Other Income Expense Net | -812000 | -196000 | N/A | N/A | 613000 |
| Net Income From Continuing Operations | 21.15 million | -1.27 million | N/A | N/A | 11.7 million |
| Net Income Applicable to Common Shares | 9.65 million | -5.26 million | -7.36 million | 21.68 million | 6.28 million |
Cash Flow:
| Date | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 | Mar 31 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -1.46 million | N/A | N/A |
| Change to Liabilities | -12.59 million | 1.8 million | 3.97 million | 11.28 million | -7.74 million |
| Total Cash Flow from Investing Activities | 25.65 million | -32.3 million | -3.83 million | -5.78 million | -557000 |
| Net Borrowings | 5.93 million | 2.13 million | -2.01 million | N/A | -1.32 million |
| Total Cash Flow from Financial Activities | N/A | N/A | 44000 | 85000 | -1.15 million |
| Change to Operating Activities | -4.18 million | 381000 | 1.07 million | -693000 | 639000 |
| Change in Cash | N/A | N/A | 5 million | 2.65 million | -9.12 million |
| Total Cash from Operating Activities | -18.24 million | 26.45 million | 11.61 million | 9.72 million | -8.7 million |
| Depreciation | N/A | N/A | 1.21 million | 1.18 million | 1.04 million |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | 1.89 million | -3.7 million | -4.08 million |
| Change to Account Receivables | N/A | N/A | -12.29 million | -19.43 million | -2.96 million |
| Other Cash Flow from Financing Activities | 716000 | 622000 | 2.05 million | 85000 | 174000 |
| Change to Net Income | -1.75 million | 6.72 million | 3.6 million | 5.55 million | 1.68 million |
| Capital Expenditures | N/A | N/A | 2.37 million | 5.79 million | 557000 |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 281.31 million | 191.38 million | N/A | N/A | 96.98 million |
| Total Stockholder Equity | 306.39 million | 279.68 million | N/A | N/A | 266.3 million |
| Other Current Liabilities | 39.84 million | 20.85 million | N/A | N/A | 14.37 million |
| Total Assets | 658.56 million | 529.37 million | N/A | N/A | 410.65 million |
| Common Stock | 99000 | 99000 | 99000 | 99000 | 99000 |
| Other Current Assets | 3.48 million | 3.21 million | N/A | N/A | N/A |
| Retained Earnings | 87.3 million | 77.65 million | 82.91 million | 90.26 million | 68.58 million |
| Other Liabilities | 6.72 million | 6.58 million | 5.5 million | 5.71 million | 8.61 million |
| Other Assets | 34.86 million | 25.23 million | 25.06 million | 21.75 million | 17.54 million |
| Cash | 150.24 million | 141.34 million | N/A | N/A | 156.7 million |
| Total Current Liabilities | 193.86 million | 113.52 million | N/A | N/A | 74.27 million |
| Other Stockholder Equity | 1.56 million | -7.55 million | -7.96 million | -4.32 million | -9.59 million |
| Property, Plant & Equipment | 197.46 million | 164.85 million | 78.91 million | 80.95 million | 79.76 million |
| Total Current Assets | 424.77 million | 338 million | N/A | N/A | 313.36 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 304.91 million | 278.39 million | 283.76 million | 294 million | 266.3 million |
| Short Term Investments | 33.88 million | 35.39 million | N/A | N/A | 19.59 million |
| Long Term Debt | 23.12 million | 16.28 million | N/A | N/A | 7.84 million |
| Inventory | 56.69 million | 45.76 million | N/A | N/A | 29.47 million |
| Accounts Payable | 117 million | 70.83 million | N/A | N/A | 55.19 million |
Sinovac Biotech Ltd (SVA) Chart:
Sinovac Biotech Ltd (SVA) News:
Below you will find a list of latest news for Sinovac Biotech Ltd (SVA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Sinovac Biotech Ltd (SVA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Sinovac Biotech Ltd (SVA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920078469/0001104659-20-078469-index.htm |
| 2018-01-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1084201/000000000018002196/0000000000-18-002196-index.htm |
| 2017-02-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1084201/000090221917000376/0000902219-17-000376-index.htm |
| 2018-02-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1084201/000090221918000018/0000902219-18-000018-index.htm |
| 2018-07-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1084201/000090445418000467/0000904454-18-000467-index.htm |
| 2019-03-19 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1084201/000092963819000368/0000929638-19-000368-index.htm |
| 2019-11-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465919064902/0001104659-19-064902-index.htm |
| 2019-12-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465919076914/0001104659-19-076914-index.htm |
| 2020-02-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920023900/0001104659-20-023900-index.htm |
| 2020-02-21 | 8-A12B/A | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920023911/0001104659-20-023911-index.htm |
| 2020-04-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920046372/0001104659-20-046372-index.htm |
| 2020-04-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920047952/0001104659-20-047952-index.htm |
| 2020-04-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920054500/0001104659-20-054500-index.htm |
| 2020-05-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920057275/0001104659-20-057275-index.htm |
| 2020-05-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920063161/0001104659-20-063161-index.htm |
| 2020-05-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920065137/0001104659-20-065137-index.htm |
| 2020-06-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920072241/0001104659-20-072241-index.htm |
| 2020-06-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920073145/0001104659-20-073145-index.htm |
| 2020-06-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920076447/0001104659-20-076447-index.htm |
| 2020-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920078469/0001104659-20-078469-index.htm |
| 2020-07-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920080953/0001104659-20-080953-index.htm |
| 2020-08-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920098489/0001104659-20-098489-index.htm |
| 2020-08-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920100245/0001104659-20-100245-index.htm |
| 2020-09-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920107664/0001104659-20-107664-index.htm |
| 2020-09-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920107666/0001104659-20-107666-index.htm |
| 2020-09-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000110465920109473/0001104659-20-109473-index.htm |
| 2016-08-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420416120848/0001144204-16-120848-index.htm |
| 2016-10-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420416127478/0001144204-16-127478-index.htm |
| 2016-10-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420416128847/0001144204-16-128847-index.htm |
| 2016-11-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420416132234/0001144204-16-132234-index.htm |
| 2016-12-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420416141104/0001144204-16-141104-index.htm |
| 2017-02-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417006584/0001144204-17-006584-index.htm |
| 2017-03-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417016364/0001144204-17-016364-index.htm |
| 2017-03-24 | 8-A12B/A | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417016366/0001144204-17-016366-index.htm |
| 2017-05-01 | NT 20-F | Notification of inability to timely file Form 20-F | https://www.sec.gov/Archives/edgar/data/1084201/000114420417023450/0001144204-17-023450-index.htm |
| 2017-05-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417027949/0001144204-17-027949-index.htm |
| 2017-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417033924/0001144204-17-033924-index.htm |
| 2017-06-27 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1084201/000114420417034228/0001144204-17-034228-index.htm |
| 2017-06-27 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1084201/000114420417034230/0001144204-17-034230-index.htm |
| 2017-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417035049/0001144204-17-035049-index.htm |
| 2017-06-30 | 8-A12B/A | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417035055/0001144204-17-035055-index.htm |
| 2017-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417042642/0001144204-17-042642-index.htm |
| 2017-11-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417056214/0001144204-17-056214-index.htm |
| 2017-11-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417057299/0001144204-17-057299-index.htm |
| 2017-11-22 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417060660/0001144204-17-060660-index.htm |
| 2017-11-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417060691/0001144204-17-060691-index.htm |
| 2017-11-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417061585/0001144204-17-061585-index.htm |
| 2017-12-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417061780/0001144204-17-061780-index.htm |
| 2017-12-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417061781/0001144204-17-061781-index.htm |
| 2017-12-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420417065708/0001144204-17-065708-index.htm |
| 2018-01-05 | SC 13E3 | Going private transaction by certain issuers | https://www.sec.gov/Archives/edgar/data/1084201/000114420418000917/0001144204-18-000917-index.htm |
| 2018-01-30 | SC 13E3/A | Going private transaction by certain issuers | https://www.sec.gov/Archives/edgar/data/1084201/000114420418004421/0001144204-18-004421-index.htm |
| 2018-01-30 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1084201/000114420418004422/0001144204-18-004422-index.htm |
| 2018-02-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418006114/0001144204-18-006114-index.htm |
| 2018-03-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418012931/0001144204-18-012931-index.htm |
| 2018-03-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418013074/0001144204-18-013074-index.htm |
| 2018-03-06 | 8-A12B/A | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418013077/0001144204-18-013077-index.htm |
| 2018-03-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418014790/0001144204-18-014790-index.htm |
| 2018-03-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418017019/0001144204-18-017019-index.htm |
| 2018-04-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418021255/0001144204-18-021255-index.htm |
| 2018-04-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418021267/0001144204-18-021267-index.htm |
| 2018-04-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418021870/0001144204-18-021870-index.htm |
| 2018-04-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418022874/0001144204-18-022874-index.htm |
| 2018-04-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418022879/0001144204-18-022879-index.htm |
| 2018-04-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418023594/0001144204-18-023594-index.htm |
| 2018-04-30 | NT 20-F | Notification of inability to timely file Form 20-F | https://www.sec.gov/Archives/edgar/data/1084201/000114420418023852/0001144204-18-023852-index.htm |
| 2018-05-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418024580/0001144204-18-024580-index.htm |
| 2018-05-08 | NT 20-F/A | Notification of inability to timely file Form 20-F | https://www.sec.gov/Archives/edgar/data/1084201/000114420418025875/0001144204-18-025875-index.htm |
| 2018-05-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418026108/0001144204-18-026108-index.htm |
| 2018-05-11 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418027303/0001144204-18-027303-index.htm |
| 2018-05-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418027622/0001144204-18-027622-index.htm |
| 2018-06-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418033664/0001144204-18-033664-index.htm |
| 2018-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418035710/0001144204-18-035710-index.htm |
| 2018-07-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418037077/0001144204-18-037077-index.htm |
| 2018-07-03 | 8-A12B/A | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418037079/0001144204-18-037079-index.htm |
| 2018-07-23 | SC 13E3/A | Going private transaction by certain issuers | https://www.sec.gov/Archives/edgar/data/1084201/000114420418039200/0001144204-18-039200-index.htm |
| 2018-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418045446/0001144204-18-045446-index.htm |
| 2018-09-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418049587/0001144204-18-049587-index.htm |
| 2018-10-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418053084/0001144204-18-053084-index.htm |
| 2018-10-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418053908/0001144204-18-053908-index.htm |
| 2018-10-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418054099/0001144204-18-054099-index.htm |
| 2018-10-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418054648/0001144204-18-054648-index.htm |
| 2018-11-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418058119/0001144204-18-058119-index.htm |
| 2018-11-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418062066/0001144204-18-062066-index.htm |
| 2018-12-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418064346/0001144204-18-064346-index.htm |
| 2018-12-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420418065492/0001144204-18-065492-index.htm |
| 2019-02-22 | 8-A12G | Registration of securities [Section 12(g)] | https://www.sec.gov/Archives/edgar/data/1084201/000114420419009655/0001144204-19-009655-index.htm |
| 2019-02-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420419009657/0001144204-19-009657-index.htm |
| 2019-02-22 | 8-A12B | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1084201/000114420419009658/0001144204-19-009658-index.htm |
| 2019-03-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420419013112/0001144204-19-013112-index.htm |
| 2019-04-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420419019580/0001144204-19-019580-index.htm |
| 2019-04-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420419019804/0001144204-19-019804-index.htm |
| 2019-04-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420419022195/0001144204-19-022195-index.htm |
| 2019-07-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420419034351/0001144204-19-034351-index.htm |
| 2019-08-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1084201/000114420419040319/0001144204-19-040319-index.htm |
| 2017-07-07 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1084201/000121465917004388/0001214659-17-004388-index.htm |
| 2018-03-26 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1084201/000121465918002332/0001214659-18-002332-index.htm |
| 2019-04-29 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1084201/000156459019013766/0001564590-19-013766-index.htm |
| 2020-04-30 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1084201/000156459020020204/0001564590-20-020204-index.htm |
| 2018-07-11 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1084201/000161577418006389/0001615774-18-006389-index.htm |
| 2018-07-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1084201/000161577418006725/0001615774-18-006725-index.htm |
| 2018-08-27 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1084201/000161577418008663/0001615774-18-008663-index.htm |